

Schizophrenia Bulletin Index—1996–97

Author Index

A

- Adams, Catherine;** *see* Leonard, Sherry
- Adler, Lawrence E.;** *see* Leonard, Sherry
- Agresta, Julie;** *see* Mueser, Kim T.
- Allen, John S.** Are traditional societies schizophrenogenic?, 23(3):357–364, 1997.
- Alpert, Murray; Kotsaftis, Antonis; and Pouget, Enrique R.** Speech fluency and schizophrenic negative signs, 23(2):171–177, 1997.
- Ammann, Roland;** *see* Modestin, Jiri
- Anand, Ravi;** *see* Shiovitz, Thomas M.
- Anonymous.** First person account: Social, economic, and medical effects of schizophrenia, 22(1):183–185, 1996; First person account: The end of two roads, 23(1):163–164, 1997.
- Ansel, Mark;** *see* Brekke, John S.
- Apperson, L. Joy;** *see* McEvoy, Joseph P.
- Apud, Jose;** *see* Egan, Michael F.
- Arnold, Steven E., and Trojanowski, John Q.** Cognitive impairment in elderly schizophrenia: A dementia (still) lacking distinctive histopathology, 22(1):5–9, 1996.
- Aronson, Andrew;** *see* Bergman, Andrea J.
- Assouly-Besse, Francoise;** *see* Dollfus, Sonia
- B**
- Bachneff, Svetlozar A.** Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis, 22(1):163–182, 1996.
- Barrio, Concepcion;** *see* Brekke, John S.
- Barrowclough, Christine; Tarrier, Nicholas; and Johnston, Marie.** Distress, expressed emotion, and attributions in relatives of schizophrenia patients, 22(4):691–702, 1996.
- Battaglia, Marco, and Bellodi, Laura.** Familial risks and reproductive fitness in schizophrenia, 22(2):191–195, 1996.
- Battaglia, Marco; Cavallini, Maria Cristina; Macchiardi, Fabio; and Bellodi, Laura.** The structure of *DSM-III-R* schizotypal personality disorder diagnosed by direct interview, 23(1):83–92, 1997.
- Bayley, Robert.** First person account: Schizophrenia, 22(4):727–729, 1996.
- Bell, Morris D., and Lysaker, Paul H.** Clinical benefits of paid work activity in schizophrenia: 1-year followup, 23(2):317–328, 1997.
- Bell, Morris D.; Lysaker, Paul H.; and Milstein, Robert M.** Clinical benefits of paid work activity in schizophrenia, 22(1):51–67, 1996.
- Bellack, Alan S.; Blanchard, Jack J.; and Mueser, Kim T.** Cue availability and affect perception in schizophrenia, 22(3):535–544, 1996.
- Bellodi, Laura;** *see* Battaglia, Marco
- Benes, Francine M.** What an archaeological dig can tell us about macro- and microcircuitry in brains of schizophrenia subjects, 23(3):503–507, 1997.
- Benishay, Deana;** *see* Raine, Adrian
- Bergman, Andrea J.; Harvey, Philip D.; Mitropoulou, Vivian; Aronson, Andrew; Marder, Dova; Silverman, Jeremy; Trestman, Robert; and Siever, Larry J.** The factor structure of schizotypal symptoms in a clinical population, 22(3):501–509, 1996.
- Berman, Nancy;** *see* Maas, James W.
- Bickford, Paula;** *see* Leonard, Sherry
- Bird, Laura;** *see* Brekke, John S.
- Blanchard, Jack J.;** *see* Bellack, Alan S.
- Blyler, Crystal R.;** *see* Fenton, Wayne S.
- Bogerts, Bernhard.** The temporolimbic system theory of positive schizophrenic symptoms, 23(3):423–435, 1997.
- Bowden, Charles L.;** *see* Maas, James W.
- Braff, David L., and Swerdlow, Neal R.** Neuroanatomy of schizophrenia, 23(3):509–512, 1997.
- Breese, Charles R.;** *see* Leonard, Sherry
- Brekke, John S., and Barrio, Concepcion.** Cross-ethnic symptom differences in schizophrenia: The influence of culture and minority status, 23(2):305–316, 1997.
- Brekke, John S.; Raine, Adrian; Ansel, Mark; Lencz, Todd; and Bird, Laura.** Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia, 23(1):19–28, 1997.
- Bromet, Evelyn;** *see* Kovasznay, Beatrice

- Brown, Georgia P.** First person account: Paranoid schizophrenia—A sibling's story, 22(3):557–561, 1996.
- Buchanan, Robert W.;** *see* Conley, Robert R.
- Buchanan, Robert W., and Carpenter, William T., Jr.** The neuroanatomies of schizophrenia, 23(3):367–372, 1997.
- Buchanan, Robert W.; Stevens, Janice R.; and Carpenter, William T., Jr.** The neuroanatomy of schizophrenia: Editors' introduction, 23(3):365–366, 1997.
- Budd, Richard J., and Hughes, Ian C.T.** What do relatives of people with schizophrenia find helpful about family intervention?, 23(2):341–347, 1997.
- Buican, Brett J.;** *see* Corrigan, Patrick W.
- Bunk, Detlef;** *see* Eggers, Christian
- Byerley, William;** *see* Leonard, Sherry

C

- Cannon, Tyrone D.;** *see* Olin, Su-chin Serene
- Carpenter, William T., Jr.** The risk of medication-free research, 23(1):11–18, 1997; *see also* Buchanan, Robert W.
- Carr, Tom J.;** *see* Stanley, Jeff A.
- Carver, Lawrence;** *see* Essock, Susan M.
- Casanova, Manuel F.** Functional and anatomical aspects of prefrontal pathology in schizophrenia, 23(3):517–519, 1997; The temporolimbic system theory of paranoid schizophrenia, 23(3):513–515, 1997.
- Casey, Daniel E.;** *see* Hansen, Thomas E.
- Caudle, Jane;** *see* Lewine, Richard
- Cavallini, Maria Cristina;** *see* Battaglia, Marco
- Chapman, Jean P.;** *see* Kwapil, Thomas R.
- Chapman, Loren J.;** *see* Kwapil, Thomas R.
- Claudel, Bertrand;** *see* Plagnol, Arnaud

- Comtois, Katherine Anne;** *see* Ries, Richard K.
- Conley, Robert R., and Buchanan, Robert W.** Evaluation of treatment resistance in schizophrenia, 23(4):663–674, 1997.
- Coon, Hilary;** *see* Leonard, Sherry
- Cooper, Thomas B.;** *see* Volavka, Jan
- Corrigan, Patrick W.; Silverman, Randy; Stephenson, James; Nugent-Hirschbeck, Joyce; and Buican, Brett J.** Situational familiarity and feature recognition in schizophrenia, 22(1):153–161, 1996.
- Coverdale, John H.;** *see* Falloon, Ian R.H.
- Crider, Andrew.** Perseveration in schizophrenia, 23(1):63–74, 1997.
- Crow, Timothy J.** Temporolimbic or transcallosal connections: Where is the primary lesion in schizophrenia and what is its nature?, 23(3):512–523, 1997; *see also* DeLisi, Lynn E.
- Cutler, Neal R.;** *see* Shiovitz, Thomas M.
- Czobor, Pál, and Volavka, Jan.** Positive and negative symptoms: Is their change related?, 22(4):577–590, 1996.

D

- Davidson, Michael;** *see* Harvey, Philip D.
- de Leon, José.** Smoking and vulnerability for schizophrenia, 22(3):405–409, 1996; *see also* Verghese, Cherian
- Delahunty, Ann;** *see* Morice, Rodney
- DeLisi, Lynn E.; Sakuma, Michael; Kushner, Maureen; Finer, Daniel L.; Hoff, Anne L.; and Crow, Timothy J.** Anomalous cerebral asymmetry and language processing in schizophrenia, 23(2):255–271, 1997.
- Dingemans, Peter M.;** *see* Linszen, Donald H.
- Dohm, Faith-Anne;** *see* Essock, Susan M.
- Doig, Alex;** *see* Gruzelier, John H.
- Dollfus, Sonia; Everitt, Brian; Ribeyre, Jean Marie; Assouly-Besse, Francoise; Sharp, Charlie;**

and Petit, Michel. Identifying subtypes of schizophrenia by cluster analyses, 22(3):545–555, 1996.

Donchin, Emanuel; *see* McCarley, Robert W.

Draine, Jeffrey; *see* Solomon, Phyllis

Drake, Robert E.; *see* Goodman, Lisa A.

Drost, Dick J.; *see* Stanley, Jeff A.

Dwork, Andrew J. Postmortem studies of the hippocampal formation in schizophrenia, 23(3):385–402, 1997.

Dykstra, Tracey. First person account: How I cope, 23(4):697–699, 1997.

E

Edwards, Jane; *see* McGorry, Patrick D.

Egan, Michael F.; Apud, Jose; and Wyatt, Richard Jed. Treatment of tardive dyskinesia, 23(4):583–609, 1997.

Eggers, Christian, and Bunk, Detlef. The long-term course of childhood-onset schizophrenia: A 42-year followup, 23(1):105–117, 1997.

Eronen, Markku; Tiihonen, Jari; and Hakola, Panu. Schizophrenia and homicidal behavior, 22(1):83–89, 1996.

Essock, Susan M.; Hargreaves, William A.; Dohm, Faith-Anne; Goethe, John; Carver, Lawrence; and Hipshman, Lawrence. Clozapine eligibility among State hospital patients, 22(1):15–25, 1996.

Everitt, Brian; *see* Dollfus, Sonia

F

Falloon, Ian R.H.; Kydd, Robert R.; Coverdale, John H.; and Laidlaw, Tannis M. Early detection and intervention for initial episodes of schizophrenia, 22(2):271–282, 1996.

Farber, Nuri B.; *see* Olney, John W.

Fenton, Wayne S.; Blyler, Crystal R.; and Heinssen, Robert K. Determinants of medication compliance in schizophrenia: Empirical and clinical findings, 23(4):637–651, 1997.

Fenton, Wayne S., and Kane, John

- M. Clinical challenges in the psychopharmacology of schizophrenia: Editors' introduction, 23(4):563-565, 1997.
- Finer, Daniel;** *see* DeLisi, Lynn E.
- Fink, Max, and Sackeim, Harold A.** Convulsive therapy in schizophrenia?, 22(1):27-39, 1996.
- Fleischer, Jennifer;** *see* Kovasznay, Beatrice
- Freedman, Robert;** *see* Leonard, Sherry; McCarley, Robert W.
- Frith, Christopher D.** Functional brain imaging and the neuropathology of schizophrenia, 23(3):525-527, 1997.
- Fudge, Julie L.;** *see* Haber, Suzanne N.
- Funderburg, Linda G.;** *see* Maas, James W.
- ## G
- George, Tony P.;** *see* Ziedonis, Douglas M.
- Gladsjo, Julie Akiko;** *see* Jeste, Dilip V.
- Godwin, Sandra;** *see* McEvoy, Joseph P.
- Goethe, John;** *see* Essock, Susan M.
- Goldberg, Joseph F.;** *see* Harrow, Martin
- Goldman-Rakic, Patricia S., and Selem, Lynn D.** Functional and anatomical aspects of prefrontal pathology in schizophrenia, 23(3):437-458, 1997.
- Goodman, Lisa A.; Rosenberg, Stanley D.; Mueser, Kim T.; and Drake, Robert E.** Physical and sexual assault history in women with serious mental illness: Prevalence, correlates, treatment, and future research directions, 23(4):685-696, 1997.
- Gottesman, Irving I.;** *see* Moldin, Steven O.
- Gottesman, Irving I., and Groome, Carol S.** HIV/AIDS risks as a consequence of schizophrenia, 23(4):675-684, 1997.
- Gottlieb, Diane;** *see* McEvoy, Joseph P.
- Granger, Bernard;** *see* Plagnol, Arnaud
- Graybiel, Ann M.** The basal ganglia and cognitive pattern generators, 23(3):459-469, 1997.
- Griffith, Jay M.;** *see* Leonard, Sherry
- Groome, Carol S.;** *see* Gottesman, Irving I.
- Gruzelier, John H.** The factorial structure of schizotypy: Part I. Affinities with syndromes of schizophrenia, 22(4):611-620, 1996.
- Gruzelier, John H., and Doig, Alex.** The factorial structure of schizotypy: Part II. Cognitive asymmetry, arousal, handedness, and sex, 22(4):621-634, 1996.
- ## H
- Haber, Suzanne N., and Fudge, Julie L.** The interface between dopamine neurons and the amygdala: Implications for schizophrenia, 23(3):471-482, 1997.
- Haden, Catherine;** *see* Lewine, Richard
- Hakola, Panu;** *see* Eronen, Markku
- Halbreich, Uriel, and Palter, Steven.** Accelerated osteoporosis in psychiatric patients: Possible pathophysiological processes, 22(3):447-454, 1996.
- Halford, W. Kim;** *see* Hayes, Robyn L.
- Hansen, Thomas E.; Casey, Daniel E.; and Hoffman, William F.** Neuroleptic intolerance, 23(4):567-582, 1997.
- Hargreaves, William A.;** *see* Essock, Susan M.
- Harrigan, Susan M.;** *see* McGorry, Patrick D.
- Harrow, Martin;** *see* Marengo, Joanne T.
- Harrow, Martin; Sands, James R.; Silverstein, Marshall L.; and Goldberg, Joseph F.** Course and outcome for schizophrenia versus other psychotic patients: A longitudinal study, 23(2):287-303, 1997.
- Hartman, Marilyn;** *see* McEvoy, Joseph P.
- Hartman, Richard D.;** *see* Shiovitz, Thomas M.
- Harvey, Ian;** *see* Takei, Noriyoshi
- Harvey, Philip D.;** *see* Bergman, Andrea J.
- Harvey, Philip D.; Davidson, Michael; Mueser, Kim T.; Parrella, Michael; White, Leonard; and Powchik, Peter.** Social-Adaptive Functioning Evaluation (SAFE): A rating scale for geriatric psychiatric patients, 23(1):131-145, 1997.
- Hayes, Robyn L., and Halford, W. Kim.** Time use of unemployed and employed single male schizophrenia subjects, 22(4):659-669, 1996.
- Heckers, Stephan.** Neuropathology of schizophrenia: Cortex, thalamus, basal ganglia, and neurotransmitter-specific projection systems, 23(3):403-421, 1997.
- Heinssen, Robert K.;** *see* Fenton, Wayne S.
- Hipshman, Lawrence;** *see* Essock, Susan M.
- Hoff, Anne L.;** *see* DeLisi, Lynn E.
- Hoffman, William F.;** *see* Hansen, Thomas E.
- Horn, David;** *see* Rupp, Eytan
- Hsiao, John K.;** *see* McCarley, Robert W.; Shore, David
- Hughes, Ian C.T.;** *see* Budd, Richard J.
- Hyde, Thomas M., and Weinberger, Daniel R.** Seizures and schizophrenia, 23(4):611-622, 1997.
- ## J
- Jackson, Henry J.;** *see* McGorry, Patrick D.; Yung, Alison R.
- Jandorf, Lina;** *see* Kovasznay, Beatrice
- Javors, Martin A.;** *see* Maas, James W.
- Jeste, Dilip V.; Gladsjo, Julie Akiko; Lindamer, Laurie A.; and Lacro, Jonathan P.** Medical comorbidity in schizophrenia, 22(3):413-430, 1996.

- Johannessen, Jan Olav;** *see* Larsen, Tor K.; McGlashan, Thomas H.
- Johnston, Marie;** *see* Barrowclough, Christine
- Jones, Edward G.** Cortical development and thalamic pathology in schizophrenia, 23(3):483-501, 1997.
- Jones, Peter;** *see* Takei, Noriyoshi
- Josiassen, Richard C.; *see* Verghese, Chierian**
- Josiassen, Richard C., and Schindler, Barbara.** Medical comorbidity and schizophrenia: Editors' introduction, 22(3):411-412, 1996.
- Junginger, John.** Psychosis and violence: The case for a content analysis of psychotic experience, 22(1):91-103, 1996.
- K**
- Kane, John M.;** *see* Fenton, Wayne S.; Umbricht, Daniel
- Kendler, Kenneth S.; Thacker, Leroy; and Walsh, Dermot.** Self-report measures of schizotypy as indices of familial vulnerability to schizophrenia, 22(3):511-520, 1996.
- Kosten, Therese A.** Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats, 23(2):203-213, 1997.
- Kosten, Thomas R.** Foreword, 23(2):179-180, 1997.
- Kosten, Thomas R., and Ziedonis, Douglas M.** Substance abuse and schizophrenia: Editors' introduction, 23(2):181-186, 1997.
- Kotsaftis, Antonis;** *see* Alpert, Murray
- Kovaszny, Beatrice; Fleischer, Jennifer; Tanenberg-Karant, Marsha; Jandorf, Lina; Miller, Alan D.; and Bromet, Evelyn.** Substance use disorder and the early course of illness in schizophrenia and affective psychosis, 23(2):195-201, 1997.
- Kurtz, Neil M.;** *see* Shiovitz, Thomas M.
- Kushner, Maureen;** *see* DeLisi, Lynn E.

- Kwapil, Thomas R.; Chapman, Jean P.; Chapman, Loren J.; and Miller, Michael B.** Deviant olfactory experiences as indicators of risk for psychosis, 22(2):371-382, 1996.
- Kydd, Robert R.;** *see* Falloon, Ian R.H.

L

- Lacro, Jonathan P.;** *see* Jeste, Dilip V.
- Laidlaw, Tannis M.;** *see* Falloon, Ian R.H.
- Larsen, Tor K.; McGlashan, Thomas H.; Johannessen, Jan Olav; and Vibe-Hansen, Lars.** First-episode schizophrenia: II. Premorbid patterns by gender, 22(2):257-269, 1996.
- Larsen, Tor K.; McGlashan, Thomas H.; and Moe, Lars Conrad.** First-episode schizophrenia: I. Early course parameters, 22(2):241-256, 1996.
- Laska, Eugene M.;** *see* Volavka, Jan
- Lee, Heidi;** *see* Sheitman, Brian B.
- Lencz, Todd;** *see* Brekke, John S.; Raine, Adrian
- Lenior, Marie A.;** *see* Linszen, Donald H.
- Leonard, Sherry; Adams, Catherine; Breese, Charles R.; Adler, Lawrence E.; Bickford, Paula; Byerley, William; Coon, Hilary; Griffith, Jay M.; Miller, Christine; Myles-Worsley, Marina; Nagamoto, Herbert T.; Rollins, Yvonne; Stevens, Karen E.; Waldo, Merilyn; and Freedman, Robert.** Nicotinic receptor function in schizophrenia, 22(3):431-445, 1996.

- Lewine, Richard; Haden, Catherine; Caudle, Jane; and Shurett, Rebecca.** Sex-onset effects on neuropsychological function in schizophrenia, 23(1):51-61, 1997.
- Lewis, David A.** Schizophrenia and disordered neural circuitry, 23(3):529-531, 1997.
- Lewis, Shon;** *see* Takei, Noriyoshi
- Lieberman, Jeffrey A.;** *see* Sheitman, Brian B.

- Lindamer, Laurie A.;** *see* Jeste, Dilip V.
- Linszen, Donald H.; Dingemans, Peter M.; Nugter, M. Annet; Van der Does, A. Jan Willem; Scholte, Willem F.; and Lenior, Marie A.** Patient attributes and expressed emotion as risk factors for psychotic relapse, 23(1):119-130, 1997.
- Lysaker, Paul H.;** *see* Bell, Morris D.

M

- Maas, James W.; Bowden, Charles L.; Miller, Alexander L.; Javors, Martin A.; Funderburg, Linda G.; Berman, Nancy; and Weintraub, Susan T.** Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations, 23(1):147-154, 1997.
- Macciardi, Fabio;** *see* Battaglia, Marco
- Malla, Ashok;** *see* Stanley, Jeff A.
- Mannion, Edie;** *see* Solomon, Phyllis
- Marder, Dora;** *see* Bergman, Andrea J.
- Marengo, Joanne T., and Harrow, Martin.** Longitudinal courses of thought disorder in schizophrenia and schizoaffective disorder, 23(2):273-285, 1997.
- Mattes, Jeffrey A.** Risperidone: How good is the evidence for efficacy?, 23(1):155-161, 1997.
- McCarley, Robert W.; Hsiao, John K.; Freedman, Robert; Pfefferbaum, Adolf; and Donchin, Emanuel.** Neuroimaging and the cognitive neuroscience of schizophrenia, 22(4):703-725, 1996.
- McEvoy, Joseph P.; Hartman, Marilyn; Gottlieb, Diane; Godwin, Sandra; Apperson, L. Joy; and Wilson, William.** Common sense, insight, and neuropsychological test performance in schizophrenia patients, 22(4):635-641, 1996.
- McFarlane, Colleen A.;** *see* Yung, Alison R.
- McGeer, Patrick L.;** *see* Oken, Robert J.

McGlashan, Thomas H. Early detection and intervention in schizophrenia: Editors' introduction, 22(2):197-199, 1996; Early detection and intervention in schizophrenia: Research, 22(2):327-345, 1996; *see also* Larsen, Tor K.

McGlashan, Thomas H., and Johannessen, Jan Olav. Early detection and intervention with schizophrenia: Rationale, 22(2):201-222, 1996.

McGorry, Patrick D.; *see* Yung, Alison R.

McGorry, Patrick D.; Edwards, Jane; Mihalopoulos, Cathrine; Harrigan, Susan M.; and Jackson, Henry J. EPPIC: An evolving system of early detection and optimal management, 22(2):305-326, 1996.

Mednick, Sarnoff A.; *see* Olin, Su-chin Serene

Meisel, Marilyn; *see* Solomon, Phyllis

Meisner, Morris; *see* Volavka, Jan

Mihalopoulos, Cathrine; *see* McGorry, Patrick D.

Miller, Alan D.; *see* Kovasznay, Beatrice

Miller, Alexander L.; *see* Maas, James W.

Miller, Christine; *see* Leonard, Sherry

Miller, Laura J. Sexuality, reproduction, and family planning in women with schizophrenia, 23(4):623-635, 1997.

Miller, Michael B.; *see* Kwapil, Thomas R.

Milstein, Robert M.; *see* Bell, Morris D.

Miner, Christian R.; *see* Rosenthal, Richard N.

Mitropoulou, Vivian; *see* Bergman, Andrea J.

Modestin, Jiri, and Ammann, Roland. Mental disorder and criminality: Male schizophrenia, 22(1):69-82, 1996.

Moe, Lars Conrad; *see* Larsen, Tor K.

Moldin, Steven O., and Gottesman, Irving I. Genes, experience, and chance in schizophrenia—Position-

ing for the 21st century, 23(4):547-561, 1997.

Molta, Victoria E. First person account: Living with mental illness, 23(2):349-351, 1997.

Morice, Rodney, and Delahunty, Ann. Frontal/executive impairments in schizophrenia, 22(1):125-137, 1996.

Mueser, Kim T.; *see* Bellack, Alan S.; Goodman, Lisa A.; Harvey, Philip D.

Mueser, Kim T.; Valentiner, David P.; and Agresta, Julie. Coping with negative symptoms of schizophrenia: Patient and family perspectives, 23(2):329-339, 1997.

Murphy, Marcia A. First person account: Meaning of psychoses, 23(3):541-543, 1997.

Murray, Robin M.; *see* Takei, Noriyoshi

Myles-Worsley, Marina; *see* Leonard, Sherry

N

Nagamoto, Herbert T.; *see* Leonard, Sherry

Nugent-Hirschbeck, Joyce; *see* Corrigan, Patrick W.

Nugter, M. Annet; *see* Linszen, Donald H.

O

Oken, Robert J., and McGeer, Patrick L. Schizophrenia, Alzheimer's disease, and anti-inflammatory agents, 22(1):1-4, 1996.

Olin, Su-chin Serene, and Mednick, Sarnoff A. Risk factors of psychosis: Identifying vulnerable populations premorbidly, 22(2):223-240, 1996.

Olin, Su-chin Serene; Raine, Adrian; Cannon, Tyrone D.; Parnas, Josef; Schulsinger, Fini; and Mednick, Sarnoff A. Childhood behavior precursors of schizotypal personality disorder, 23(1):93-103, 1997.

Olney, John W., and Farber, Nuri B. Discussion of Bogerts' temporolimbic system theory of paranoid schizophrenia, 23(3):533-536, 1997.

P

Pachoud, Bernard; *see* Plagnol, Arnaud

Palter, Steven; *see* Halbreich, Uriel

Parnas, Josef; *see* Olin, Su-chin Serene

Parrella, Michael; *see* Harvey, Philip D.

Patton, George C.; *see* Yung, Alison R.

Petit, Michel; *see* Dollfus, Sonia

Pfefferbaum, Adolf; *see* McCarley, Robert W.

Plagnol, Arnaud; Pachoud, Bernard; Claudel, Bertrand; and Granger, Bernard. Functional disorganization of representations in schizophrenia, 22(2):383-398, 1996.

Pouget, Enrique R.; *see* Alpert, Murray

Powchik, Peter; *see* Harvey, Philip D.

R

Raine, Adrian; *see* Brekke, John S.; Olin, Su-chin Serene

Raine, Adrian; Benishay, Deana; Lencz, Todd; and Scarpa, Angela. Abnormal orienting in schizotypal personality disorder, 23(1):75-82, 1997.

Rakkar, Arun; *see* Yung, Alison R.

Reggia, James A.; *see* Ruppert, Eytan

Ribeyre, Jean Marie; *see* Dollfus, Sonia

Ries, Richard K., and Comtois, Katherine Anne. Illness severity and treatment services for dually diagnosed severely mentally ill outpatients, 23(2):239-246, 1997.

Robeson, Mary R.; *see* Sanguinetti, Vincenzo R.

Rollins, Yvonne; *see* Leonard, Sherry

Rombouts, René P.; *see* van den Bosch, Robert J.

Rosenberg, Stanley D.; *see* Goodman, Lisa A.

Rosenthal, Richard N., and Miner, Christian R. Differential diagnosis of substance-induced psychosis and schizophrenia in patients with sub-

stance use disorder, 23(2):187-193, 1997.

Ruppin, Eytan; Reggia, James A.; and Horn, David. Pathogenesis of schizophrenic delusions and hallucinations: A neural model, 22(1):105-123, 1996.

Rylett, R. Jane; *see* Stanley, Jeff A.

S

Sackeim, Harold A.; *see* Fink, Max
Sakuma, Michael; *see* DeLisi, Lynn E.
Samuel, Steven E.; *see* Sanguinetti, Vincenzo R.

Sands, James R.; *see* Harrow, Martin
Sanguinetti, Vincenzo R.; Samuel, Steven E.; Schwartz, Stephen L.; and Robeson, Mary R. Gender differences among civilly committed schizophrenia subjects, 22(4):653-658, 1996.

Scarpa, Angela; *see* Raine, Adrian
Schindler, Barbara; *see* Josiassen, Richard C.

Scholte, Willem F.; *see* Linszen, Donald H.

Schulsinger, Fini; *see* Olin, Su-chin Serene

Schwartz, Stephen L.; *see* Sanguinetti, Vincenzo R.

Selemmon, Lynn D.; *see* Goldman-Rakic, Patricia S.

Sewell, Daniel D. Schizophrenia and HIV, 22(3):465-473, 1996.

Sharp, Charlie; *see* Dollfus, Sonia

Sheitman, Brian B.; Lee, Heidi; Strauss, Rael; and Lieberman, Jeffrey A. The evaluation and treatment of first-episode psychosis, 23(4):653-661, 1997.

Shiovitz, Thomas M.; Welke, Timothy L.; Tigel, Phillip D.; Anand, Ravi; Hartman, Richard D.; Sramek, John J.; Kurtz, Neil M.; and Cutler, Neal R. Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal, 22(4):591-595, 1996.

Shore, David, and Hsiao, John K. Medication-free intervals and schizophrenia research: Editors' introduction, 23(1):1, 1997.

Shurett, Rebecca; *see* Lewine, Richard

Siever, Larry J.; *see* Bergman, Andrea J.

Silverman, Jeremy; *see* Bergman, Andrea J.

Silverman, Randy; *see* Corrigan, Patrick W.

Silverstein, Marshall L.; *see* Harrow, Martin

Simpson, John C., and Tsuang, Ming T. Mortality among patients with schizophrenia, 22(3):485-499, 1996.

Solomon, Phyllis; Draine, Jeffrey; Mannion, Edie; and Meisel, Marilyn. Impact of brief family psychoeducation on self-efficacy, 22(1):41-50, 1996.

Spitzer, Manfred. A cognitive neuroscience view of schizophrenic thought disorder, 23(1):29-50, 1997.

Sramek, John J.; *see* Shiovitz, Thomas M.

Stanley, Jeff A.; Williamson, Peter C.; Drost, Dick J.; Rylett, R. Jane; Carr, Tom J.; Malla, Ashok; and Thompson, R. Terry. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients, 22(4):597-609, 1996.

Stephenson, James; *see* Corrigan, Patrick W.

Stevens, Janice R. Anatomy of schizophrenia revisited, 23(3):373-383, 1997; *see also* Buchanan, Robert W.

Stevens, Karen E.; *see* Leonard, Sherry

Strauss, Rael; *see* Sheitman, Brian B.

Swerdlow, Neal R.; *see* Braff, David L.

T

Takei, Noriyoshi; Lewis, Shon; Jones, Peter; Harvey, Ian; and Murray, Robin M. Prenatal exposure to influenza and increased cerebrospinal fluid spaces in schizophrenia, 22(3):521-534, 1996.

Tanenberg-Karant, Marsha; *see* Kovasznay, Beatrice

Tarrier, Nicholas; *see* Barrowclough, Christine

Thacker, Leroy; *see* Kendler, Kenneth S.

Thompson, R. Terry; *see* Stanley, Jeff A.

Tigel, Phillip D.; *see* Shiovitz, Thomas M.

Tiihonen, Jari; *see* Eronen, Markku

Trestman, Robert; *see* Bergman, Andrea J.

Trojanowski, John Q.; *see* Arnold, Steven E.

Trudeau, Kimberlee; *see* Ziedonis, Douglas M.

Tsuang, Ming T.; *see* Simpson, John C.

U

Umbricht, Daniel, and Kane, John M. Medical complications of new antipsychotic drugs, 22(3):475-483, 1996.

V

Vaglum, Per. Earlier detection and intervention in schizophrenia: Unsolved questions, 22(2):347-351, 1996.

Valentiner, David P.; *see* Mueser, Kim T.

van Asma, Maria J.O.; *see* van den Bosch, Robert J.

van den Bosch, Robert J.; Rombouts, René P.; and van Asma, Maria J.O. What determines Continuous Performance Task performance?, 22(4):643-651, 1996.

Van der Does, A. Jan Willem; *see* Linszen, Donald H.

Verghese, Cherian; de Leon, José; and Josiassen, Richard C. Problems and progress in the diagnosis and treatment of polydipsia and hyponatremia, 22(3):455-464, 1996.

Vibe-Hansen, Lars; *see* Larsen, Tor K.

Volavka, Jan; *see* Czobor, Pál

Volavka, Jan; Cooper, Thomas B.; Laska, Eugene M.; and Meisner, Morris. Placebo washout in trials of antipsychotic drugs, 22(4):567-576, 1996.

W

- Wagner, Pamela Spiro.** First person account: A voice from another closet, 22(2):399-401, 1996.
- Waldo, Merilyne;** *see* Leonard, Sherry
- Walsh, Dermot;** *see* Kendler, Kenneth S.
- Weinberger, Daniel R.** On localizing schizophrenic neuropathology, 23(3):537-540, 1997; *see also* Hyde, Thomas M.
- Weintraub, Susan T.;** *see* Maas, James W.
- Welke, Timothy L.;** *see* Shiovitz, Thomas M.
- White, Leonard;** *see* Harvey, Philip D.
- Wilkins, Jeffery N.** Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23(2): 215-228, 1997.
- Williams, Leanne M.** Cognitive inhibition and schizophrenic symptom subgroups, 22(1):139-151, 1996.

- Williamson, Peter C.;** *see* Stanley, Jeff A.
- Wilson, William;** *see* McEvoy, Joseph P.
- Wuerker, Anne McCarrick.** Communication patterns and expressed emotion in families of persons with mental disorders, 22(4):671-690, 1996.
- Wyatt, Richard Jed.** Research in schizophrenia and the discontinuation of antipsychotic medications, 23(1):3-9, 1997; *see also* Egan, Michael F.

Y

- Yung, Alison R., and McGorry, Patrick D.** The prodromal phase of first-episode psychosis: Past and current conceptualizations, 22(2):353-370, 1996.
- Yung, Alison R.; McGorry, Patrick D.; McFarlane, Colleen A.;**

- Jackson, Henry J.; Patton, George C.; and Rakkar, Arun.** Monitoring and care of young people at incipient risk of psychosis, 22(2):283-303, 1996.

Z

- Ziedonis, Douglas M.;** *see* Kosten, Thomas R.
- Ziedonis, Douglas M., and George, Tony P.** Schizophrenia and nicotine use: Report of a pilot smoking cessation program and review of neurobiological and clinical issues, 23(2):247-254, 1997.
- Ziedonis, Douglas M., and Trudeau, Kimberlee.** Motivation to quit using substances among individuals with schizophrenia: Implications for a motivation-based treatment model, 23(2):229-238, 1997.

Subject Index

A

- Acquired immunodeficiency syndrome**
HIV/AIDS risks as a consequence of schizophrenia, 23:675
- Adaptive functioning**
Social-Adaptive Functioning Evaluation (SAFE): A rating scale for geriatric psychiatric patients, 23:131
- Affect perception**
Cue availability and affect perception in schizophrenia, 22:535
- Affective disorders**
Mortality among patients with schizophrenia, 22:485
The prodromal phase of first-episode psychosis: Past and current conceptualizations, 22:353
Substance use disorder and the early course of illness in schizophrenia and affective psychosis, 23:195
- Age factors**
Accelerated osteoporosis in psychiatric patients: Possible pathophysiological processes, 22:447
Childhood behavior precursors of schizotypal personality disorder, 23:93
Cognitive impairment in elderly schizophrenia: A dementia (still) lacking distinctive histopathology, 22:5
Convulsive therapy in schizophrenia?, 22:27
Medical comorbidity in schizophrenia, 22:413
- Monitoring and care of young people at incipient risk of psychosis,** 22:283
- Schizophrenia, Alzheimer's disease, and anti-inflammatory agents,** 22:1
- Social-Adaptive Functioning Evaluation (SAFE): A rating scale for geriatric psychiatric patients,** 23:131
- AIDS.** *See* Acquired immunodeficiency syndrome
- Alcohol**
Motivation to quit using substances among individuals with schizophrenia: Implications for a motivation-based treatment model, 23:229
Pharmacotherapy of schizophrenia

patients with comorbid substance abuse, 23:215

Substance use disorder and the early course of illness in schizophrenia and affective psychosis, 23:195

Alcoholism

Schizophrenia and homicidal behavior, 22:83

Alogia

Speech fluency and schizophrenic negative signs, 23:171

Alphabet Span

Frontal/executive impairments in schizophrenia, 22:125

Alzheimer's disease. See also Dementia

Cognitive impairment in elderly schizophrenia: A dementia (still) lacking distinctive histopathology, 22:5

Schizophrenia, Alzheimer's disease, and anti-inflammatory agents, 22:1

Schizophrenia and disordered neural circuitry, 23:529

Amphetamine

Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Amygdala. See Neuroanatomy

Anthropology

At issue: Are traditional societies schizophrenogenic?, 23:359

Anti-inflammatory drugs

Schizophrenia, Alzheimer's disease, and anti-inflammatory agents, 22:1

Anticonvulsants

Seizures and schizophrenia, 23:359

Antipsychotic drugs. See also Neuroleptics; Treatment

Clinical challenges in the psychopharmacology of schizophrenia: Editors' introduction, 23:563

The evaluation and treatment of first-episode psychosis, 23:653

Evaluation of treatment-resistant schizophrenia, 23:663

Medical complications of new antipsychotic drugs, 22:475

Medication-free intervals and schizophrenia research: Editors' introduction, 23:1

Placebo washout in trials of antipsychotic drugs, 22:567

Research in schizophrenia and the discontinuation of antipsychotic medications, 23:3

The risk of medication-free research, 23:11

Sexuality, reproduction, and family planning in women with schizophrenia, 23:623

Arousal

The factorial structure of schizotypy: Part II. Cognitive asymmetry, arousal, handedness, and sex, 22:621

Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia, 23:19

Association studies

At issue: Genes, experience, and chance in schizophrenia—Positioning for the 21st century, 23:547

Attention dysfunctions

Cognitive inhibition and schizophrenic symptom subgroups, 22:139

Auditory gating

Nicotinic receptor function in schizophrenia, 22:431

B

Basal ganglia. See Neuropathology

Behavior

Childhood behavior precursors of schizotypal personality disorder, 23:93

The interface between dopamine neurons and the amygdala: Implications for schizophrenia, 23:471

Perseveration in schizophrenia, 23:63

Physical and sexual assault history in women with serious mental illness: Prevalence, correlates, treatment, and future research directions, 23:685

Situational familiarity and feature recognition in schizophrenia, 22:153

Bipolar disorders

Communication patterns and expressed emotion in families of persons with mental disorders, 22:671

Bone mineral density

Accelerated osteoporosis in psychiatric patients: Possible pathophysiological processes, 22:447

Brain areas. See Neuroanatomy; Neuropathology

Brain asymmetry. See Cerebral asymmetry

Brain development

Seizures and schizophrenia, 23:611
Temporolimbic or transcallosal connections: Where is the primary lesion in schizophrenia and what is its nature?, 23:521

Brain morphology

Anatomy of schizophrenia revisited, 23:373

Anomalous cerebral asymmetry and language processing in schizophrenia, 23:255

Cortical development and thalamic pathology in schizophrenia, 23:483

What an archaeological dig can tell us about macro- and microcircuitry in brains of schizophrenia subjects, 23:503

Brief Psychiatric Rating Scale

Patient attributes and expressed emo-

- tion as risk factors for psychotic relapse, 23:119
Positive and negative symptoms: Is their change related?, 22:577

C

Cancer

- Medical comorbidity in schizophrenia, 22:413

Cannabis. *See* Marijuana

Cardiac side effects

- Neuroleptic intolerance, 23:567

Caregivers

- Distress, expressed emotion, and attributions in relatives of schizophrenia patients, 22:691

Carmel Workshop on Cognitive Psychophysiology

- Neuroimaging and the cognitive neuroscience of schizophrenia, 22:703

Catatonia

- Convulsive therapy in schizophrenia?, 22:27

Cerebral asymmetry

- Anomalous cerebral asymmetry and language processing in schizophrenia, 23:255
The factorial structure of schizotypy: Part II. Cognitive asymmetry, arousal, handedness, and sex, 22:621

Cerebral cortex. *See* Neuroanatomy; Neuropathology

Cerebrospinal fluid

- Prenatal exposure to influenza and increased cerebrospinal fluid spaces in schizophrenia, 22:521
Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations, 23:147

Childhood onset. *See also* Age factors

- The long-term course of childhood-onset schizophrenia: A 42-year followup, 23:105

Classification

- Cognitive inhibition and schizophrenic symptom subgroups, 22:139

Clozapine

- Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal, 22:591
Clozapine eligibility among State hospital patients, 22:15
Medical complications of new antipsychotic drugs, 22:475
Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215
Problems and progress in the diagnosis and treatment of polydipsia and hyponatremia, 22:455

Cluster analysis

- Identifying subtypes of schizophrenia by cluster analyses, 22:545

Cocaine

- Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats, 23:203
Motivation to quit using substances among individuals with schizophrenia: Implications for a motivation-based treatment model, 23:229
Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Cognition

- Functional brain imaging and the neuropathology of schizophrenia, 23:525
Longitudinal courses of thought disorder in schizophrenia and schizoaffective disorder, 23:273

Cognitive impairment

- Anomalous cerebral asymmetry and language processing in schizophrenia, 23:255
Cognitive impairment in elderly schizophrenia: A dementia (still) lacking distinctive histopathology, 22:5

- Cognitive inhibition and schizophrenic symptom subgroups, 22:139

- The factorial structure of schizotypy: Part II. Cognitive asymmetry, arousal, handedness, and sex, 22:621

- Frontal/executive impairments in schizophrenia, 22:125

- Functional and anatomical aspects of prefrontal pathology in schizophrenia, 23:525

- Functional disorganization of representations in schizophrenia, 22:383

- Medical comorbidity in schizophrenia, 22:413

- Neuroimaging and the cognitive neuroscience of schizophrenia, 22:703

- Perseveration in schizophrenia, 23:63

- Physical and sexual assault history in women with serious mental illness: Prevalence, correlates, treatment, and future research directions, 23:685

- Schizophrenia, Alzheimer's disease, and anti-inflammatory agents, 22:1

- Situational familiarity and feature recognition in schizophrenia, 22:153

- What determines Continuous Performance Task performance?, 22:643

- Cognitive inhibition and schizophrenic symptom subgroups, 22:139

Cognitive neuroscience

- A cognitive neuroscience view of schizophrenic thought disorder, 23:29

Cognitive planning

- The basal ganglia and cognitive pattern generators, 23:459

Commitment status

- Gender differences among civilly committed schizophrenia subjects, 22:653

Common sense

Common sense, insight, and neuropsychological test performance in schizophrenia patients, 22:635

Communication patterns

Communication patterns and expressed emotion in families of persons with mental disorders, 22:671

Community functioning

Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia, 23:19

Time use of unemployed and employed single male schizophrenia subjects, 22:659

Comorbidity. *See also* Substance abuse

Medical comorbidity and schizophrenia: Editors' introduction, 22:411

Medical comorbidity in schizophrenia, 22:413

Schizophrenia and HIV, 22:465

Computerized imaging. *See* Magnetic resonance imaging; Magnetic resonance spectroscopy; Positron emission tomography; Single photon emission tomography

Concretism

A cognitive neuroscience view of schizophrenic thought disorder, 23:29

Contingency management

Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Continuous Performance Task

What determines Continuous Performance Task performance?, 22:643

Controlled Word Association Test

Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia, 23:19

Coping strategies

Coping with negative symptoms of schizophrenia: Patient and family perspectives, 23:329

First person account: How I cope, 23:697

First person account: Living with mental illness, 23:349

Corpus callosum. *See* Neuropathology

Cortical circuitry. *See* Neural circuits

Course and outcome

Anatomy of schizophrenia revisited, 23:373

Clinical benefits of paid work activity in schizophrenia, 22:51

Clinical benefits of paid work activity in schizophrenia: 1-year followup, 23:317

Course and outcome for schizophrenia versus other psychotic patients: A longitudinal study, 23:287

Deviant olfactory experiences as indicators of risk for psychosis, 22:371

Early detection and intervention in schizophrenia: Research, 22:327

First-episode schizophrenia: I. Early course parameters, 22:241

First-episode schizophrenia: II. Premorbid patterns by gender, 22:257

First person account: A voice from another closet, 22:399

First person account: Living with mental illness, 23:349

The long-term course of childhood-onset schizophrenia: A 42-year followup, 23:105

Longitudinal courses of thought disorder in schizophrenia and schizoaffective disorder, 23:273

Medication-free intervals and schizophrenia research: Editors' introduction, 23:1

Research in schizophrenia and the discontinuation of antipsychotic medications, 23:3

The risk of medication-free research, 23:11

Schizophrenia and HIV, 22:465

Substance use disorder and the early course of illness in schizophrenia and affective psychosis, 23:195

Criminality. *See also* Violence

Mental disorder and criminality: Male schizophrenia, 22:69

Schizophrenia and homicidal behavior, 22:83

Cultural factors

Cross-ethnic symptom differences in schizophrenia: The influence of culture and minority status, 23:305

D

Delay of treatment

First-episode schizophrenia: I. Early course parameters, 22:241

First-episode schizophrenia: II. Premorbid patterns by gender, 22:257

Delusional disorder

Differential diagnosis of substance-induced psychosis and schizophrenia in patients with substance use disorder, 23:187

Delusions

First person account: The end of two roads, 23:163

Pathogenesis of schizophrenic delusions and hallucinations: A neural model, 22:105

Dementia. *See also* Alzheimer's disease

Cognitive impairment in elderly schizophrenia: A dementia (still) lacking distinctive histopathology, 22:5

Medical comorbidity in schizophrenia, 22:413

Demographic factors

Cross-ethnic symptom differences in schizophrenia: The influence of culture and minority status, 23:305

Depression

Mortality among patients with schizophrenia, 22:485

What determines Continuous Performance Task performance?, 22:643

Dermatologic side effects

Neuroleptic intolerance, 23:567

Desipramine

Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Digits Span Forward

Frontal/executive impairments in schizophrenia, 22:125

Disability

Course and outcome for schizophrenia versus other psychotic patients: A longitudinal study, 23:287

Disability Assessment Schedule

The long-term course of childhood-onset schizophrenia: A 42-year followup, 23:105

Dopamine

The basal ganglia and cognitive pattern generators, 23:459

A cognitive neuroscience view of schizophrenic thought disorder, 23:29

Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats, 23:203

Functional and anatomical aspects of prefrontal pathology in schizophrenia, 23:437, 517

Functional brain imaging and the neuropathology of schizophrenia, 23:525

The interface between dopamine neurons and the amygdala: Implications for schizophrenia, 23:471

Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations, 23:147

Drug discrimination

Enhanced neurobehavioral effects of

cocaine with chronic neuroleptic exposure in rats, 23:203

Dual diagnosis. See Substance abuse

E

Early detection and intervention

Earlier detection and intervention in schizophrenia: Unsolved questions, 22:347

Early detection and intervention for initial episodes of schizophrenia, 22:271

Early detection and intervention in schizophrenia: Editor's introduction, 22:197

Early detection and intervention in schizophrenia: Research, 22:327

Early detection and intervention with schizophrenia: Rationale, 22:201

EPPIC: An evolving system of early detection and optimal management, 22:305

The evaluation and treatment of first-episode psychosis, 23:653

Early Psychosis Prevention and Intervention Centre

EPPIC: An evolving system of early detection and optimal management, 22:305

Early stages of psychosis. See First-episode psychosis

Economic factors. See Socioeconomic factors

Efficacy

Coping with negative symptoms of schizophrenia: Patient and family perspectives, 23:329

Elderly persons. See Age factors

Electroconvulsive therapy

Convulsive therapy in schizophrenia?, 22:27

Employment

Clinical benefits of paid work activity in schizophrenia, 22:51

Clinical benefits of paid work activ-

ity in schizophrenia: 1-year followup, 23:317

Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia, 23:19

Time use of unemployed and employed single male schizophrenia subjects, 22:659

Environmental factors

Determinants of medication compliance in schizophrenia: Empirical and clinical findings, 23:637

Genes, experience, and chance in schizophrenia—Positioning for the 21st century, 23:547

Epidemiology

The long-term course of childhood-onset schizophrenia: A 42-year followup, 23:105

Motivation to quit using substances among individuals with schizophrenia: Implications for a motivation-based treatment model, 23:229

Prenatal exposure to influenza and increased cerebrospinal fluid spaces in schizophrenia, 22:521

Schizophrenia and homicidal behavior, 22:83

Epilepsy

Anatomy of schizophrenia revisited, 23:373

Seizures and schizophrenia, 23:611

Ethical issues

Research in schizophrenia and the discontinuation of antipsychotic medications, 23:11

The risk of medication-free research, 23:11

Ethnicity

Cross-ethnic symptom differences in schizophrenia: The influence of culture and minority status, 23:305

Event-related potentials

A cognitive neuroscience view of schizophrenic thought disorder, 23:29

Evolution

Are traditional societies schizophrenogenic?, 23:357

Expressed emotion

Are traditional societies schizophrenogenic?, 23:357

Communication patterns and expressed emotion in families of persons with mental disorders, 22:671

Distress, expressed emotion, and attributions in relatives of schizophrenia patients, 22:691

Patient attributes and expressed emotion as risk factors for psychotic relapse, 23:119

Extrapyramidal side effects

Medical complications of new antipsychotic drugs, 22:475

Neuroleptic intolerance, 23:567

Seizures and schizophrenia, 23:611

Treatment of tardive dyskinesia, 23:583

Eysenck's Psychoticism scale

Self-report measures of schizotypy as indices of familial vulnerability to schizophrenia, 22:511

F

Factor analysis

The factor structure of schizotypal symptoms in a clinical population, 22:501

The factorial structure of schizotypy: Part I. Affinities with syndromes of schizophrenia, 22:611

The factorial structure of schizotypy: Part II. Cognitive asymmetry, arousal, handedness, and sex, 22:621

Occupations, factors, and schizophrenia, 22:11

The structure of *DSM-III-R* schizotypal personality disorder diagnosed by direct interviews, 23:83

Families

Communication patterns and expressed emotion in families of

persons with mental disorders, 22:671

Coping with negative symptoms of schizophrenia: Patient and family perspectives, 23:329

Distress, expressed emotion, and attributions in relatives of schizophrenia patients, 22:691

Genes, experience, and chance in schizophrenia—Positioning for the 21st century, 23:547

Impact of brief family psychoeducation on self-efficacy, 22:41

Family intervention

Patient attributes and expressed emotion as risk factors for psychotic relapse, 23:119

What do relatives of people with schizophrenia find helpful about family intervention?, 23:341

Family planning issues

Sexuality, reproduction, and family planning in women with schizophrenia, 23:623

Family studies

Familial risks and reproductive fitness in schizophrenia, 22:191

Self-report measures of schizotypy as indices of familial vulnerability to schizophrenia, 22:511

Fertility

Familial risks and reproductive fitness in schizophrenia, 22:191

First-episode psychosis

Anomalous cerebral asymmetry and language processing in schizophrenia, 23:255

Clinical challenges in the psychopharmacology of schizophrenia: Editors' introduction, 23:563

Early detection and intervention for initial episodes of schizophrenia, 22:271

Early detection and intervention in schizophrenia: Research, 22:327

Early detection and intervention with schizophrenia: Rationale, 22:201

The evaluation and treatment of first-episode psychosis, 23:653

First-episode schizophrenia: I. Early course parameters, 22:241

First-episode schizophrenia: II. Premorbid patterns by gender, 22:257

The prodromal phase of first-episode psychosis: Past and current conceptualizations, 22:353

Sex-onset effects on neuropsychological function in schizophrenia, 23:51

Flat affect

Speech fluency and schizophrenic negative signs, 23:171

Fluency

Speech fluency and schizophrenic negative signs, 23:171

Frontal/executive impairments

Frontal/executive impairments in schizophrenia, 22:125

Frontal lobes. See Neuropathology

Functional connectivity

Cortical development and thalamic pathology in schizophrenia, 23:483

Functional brain imaging and the neuropathology of schizophrenia, 23:437, 517

Temporolimbic or transcallosal connections: Where is the primary lesion in schizophrenia and what is its nature?, 23:521

G

GABA. See Gamma-aminobutyric acid

Gamma-aminobutyric acid

Discussion of Bogerts' temporolimbic system theory of paranoid schizophrenia, 23:533

Functional and anatomical aspects of prefrontal pathology in schizophrenia, 23:437, 517

Gender factors

The factorial structure of schizotypy: Part II. Cognitive asymmetry,

arousal, handedness, and sex, 22:621

Gender differences among civilly committed schizophrenia subjects, 22:653

HIV/AIDS risks as a consequence of schizophrenia, 23:675

The long-term course of childhood-onset schizophrenia: A 42-year followup, 23:105

Mental disorder and criminality: Male schizophrenia, 22:69

Physical and sexual assault history in women with serious mental illness: Prevalence, correlates, treatment, and future research directions, 23:685

Sex-onset effects on neuropsychological function in schizophrenia, 23:51

Sexuality, reproduction, and family planning in women with schizophrenia, 23:623

Time use of unemployed and employed single male schizophrenia subjects, 22:659

Genetic factors

Early detection and intervention with schizophrenia: Rationale, 22:201

Familial risks and reproductive fitness in schizophrenia, 22:191

First-episode schizophrenia: II. Premorbid patterns by gender, 22:257

Genes, experience, and chance in schizophrenia—Positioning for the 21st century, 23:547

Medical comorbidity and schizophrenia: Editors' introduction, 22:411

Risk factors of psychosis: Identifying vulnerable populations premorbidly, 22:223

Self-report measures of schizotypy as indices of familial vulnerability to schizophrenia, 22:511

The structure of *DSM-III-R* schizotypal personality disorder diagnosed by direct interviews, 23:83

Substance abuse and schizophrenia: Editor's introduction, 23:181

Geriatric patients. *See* Age factors

Global Assessment of Functioning

First-episode schizophrenia: I. Early course parameters, 22:241

Glutamate

Functional and anatomical aspects of prefrontal pathology in schizophrenia, 23:437, 517

An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients, 22:597

Grants

Schizophrenia-related grants—Fiscal year 1995, 22:731

H

Hallucinations. *See also* Olfactory hallucinations

First person account: The end of two roads, 23:163

Pathogenesis of schizophrenic delusions and hallucinations: A neural model, 22:105

Hallucinosis

Differential diagnosis of substance-induced psychosis and schizophrenia in patients with substance use disorder, 23:187

Hand skill

Anomalous cerebral asymmetry and language processing in schizophrenia, 23:255

Handedness

The factorial structure of schizotypy: Part II. Cognitive asymmetry, arousal, handedness, and sex, 22:621

Hepatic dysfunction

Neuroleptic intolerance, 23:567

Heterogeneity

Anatomy of schizophrenia revisited, 23:373

Hippocampus. *See* Neuroanatomy

HIV. *See* Human immunodeficiency virus

Homicide. *See also* Violence

Schizophrenia and homicidal behavior, 22:83

Homosexuality

HIV/AIDS risks as a consequence of schizophrenia, 23:675

Homovanillic acid

Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations, 23:147

Hospitalization

Gender differences among civilly committed schizophrenia subjects, 22:653

Human immunodeficiency virus

HIV/AIDS risks as a consequence of schizophrenia, 23:675
Schizophrenia and HIV, 22:465

Hyponatremia

Problems and progress in the diagnosis and treatment of polydipsia and hyponatremia, 22:455

Hypotension

Medical complications of new antipsychotic drugs, 22:475

I

Influenza

Prenatal exposure to influenza and increased cerebrospinal fluid spaces in schizophrenia, 22:521

Information processing. *See also* Cognition

Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia, 23:19

Perseveration in schizophrenia, 23:63

Insight and Treatment Attitudes Questionnaire

Common sense, insight, and neuropsychological test performance in schizophrenia patients, 22:635

Instrument for the Retrospective Assessment of Onset of Schizophrenia

The long-term course of childhood-onset schizophrenia: A 42-year followup, 23:105

Intelligence

Are traditional societies schizophrenogenic?, 23:357

Frontal/executive impairments in schizophrenia, 22:125

Interviews

The structure of *DSM-III-R* schizotypal personality disorder diagnosed by direct interviews, 23:83

L

L-Dopa

A cognitive neuroscience view of schizophrenic thought disorder, 23:29

Language

Anomalous cerebral asymmetry and language processing in schizophrenia, 23:255

Temporolimbic or transcallosal connections: Where is the primary lesion in schizophrenia and what is its nature?, 23:521

Limbic system

Discussion of Bogerts' temporolimbic system theory of paranoid schizophrenia, 23:533

The interface between dopamine neurons and the amygdala: Implications for schizophrenia, 23:471

On localizing schizophrenic neuropathology, 23:537

Temporolimbic or transcallosal connections: Where is the primary lesion in schizophrenia and what is its nature?, 23:521

The temporolimbic system theory of paranoid schizophrenia, 23:513

The temporolimbic system theory of positive schizophrenic symptoms, 23:423

What an archaeological dig can tell us about macro- and microcircuitry in brains of schizophrenia subjects, 23:503

Linkage studies

At issue: Genes, experience, and chance in schizophrenia—Positioning for the 21st century, 23:547

Local circuit neurons. See Neural circuits

Locomotor sensitization

Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats, 23:203

Longitudinal studies

Course and outcome for schizophrenia versus other psychotic patients: A longitudinal study, 23:287

The long-term course of childhood-onset schizophrenia: A 42-year followup, 23:105

Longitudinal courses of thought disorder in schizophrenia and schizoaffective disorder, 23:273

Substance use disorder and the early course of illness in schizophrenia and affective psychosis, 23:195

M

Magical Ideation Scale

Deviant olfactory experiences as indicators of risk for psychosis, 22:371

Magnetic resonance imaging

Anomalous cerebral asymmetry and language processing in schizophrenia, 23:255

Magnetic resonance spectroscopy

An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients, 22:597

Marijuana

Motivation to quit using substances among individuals with schizophrenia: Implications for a motivation-based treatment model, 23:229

Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Substance use disorder and the early course of illness in schizophrenia and affective psychosis, 23:195

Medical comorbidity. See Comorbidity

Memory. See Cognitive impairment

Minority groups

Cross-ethnic symptom differences in schizophrenia: The influence of culture and minority status, 23:305

Modulation

Functional brain imaging and the neuropathology of schizophrenia, 23:525

Mortality risk

Mortality among patients with schizophrenia, 22:485

Motivation

Motivation to quit using substances among individuals with schizophrenia: Implications for a motivation-based treatment model, 23:229

Motivational enhancement therapy

Schizophrenia and nicotine use: Report of a pilot smoking cessation program and review of neurobiological and clinical issues, 23:247

Motor planning

The basal ganglia and cognitive pattern generators, 23:459

N

N-methyl-D-aspartate

- Discussion of Bogerts' temporolimbic system theory of paranoid schizophrenia, 23:533
- Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215
- Negative priming**
- Cognitive inhibition and schizophrenic symptom subgroups, 22:139
- Negative signs**
- Speech fluency and schizophrenic negative signs, 23:171
- Negative symptoms**
- Coping with negative symptoms of schizophrenia: Patient and family perspectives, 23:329
- Evaluation of treatment-resistant schizophrenia, 23:663
- Identifying subtypes of schizophrenia by cluster analyses, 22:545
- The neuroanatomies of schizophrenia, 23:367
- Positive and negative symptoms: Is their change related?, 22:577
- Substance abuse and schizophrenia: Editor's introduction, 23:181
- Neural circuits**
- The neuroanatomies of schizophrenia, 23:367
- The neuroanatomy of schizophrenia: Editors' introduction, 23:365
- Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis, 22:163
- Schizophrenia and disordered neural circuitry, 23:529
- What an archaeological dig can tell us about macro- and microcircuitry in brains of schizophrenia subjects, 23:503
- Neural modeling**
- Pathogenesis of schizophrenic delusions and hallucinations: A neural model, 22:105
- Neural networks**
- Pathogenesis of schizophrenic delusions and hallucinations: A neural model, 22:105
- Neuroanatomy. See also Neuro-pathology; Cerebral asymmetry**
- Functional and anatomical aspects of prefrontal pathology in schizophrenia, 23:525
- The interface between dopamine neurons and the amygdala: Implications for schizophrenia, 23:471
- The neuroanatomies of schizophrenia, 23:367
- Neuroanatomy of schizophrenia, 23:509
- The neuroanatomy of schizophrenia: Editors' introduction, 23:565
- Postmortem studies of the hippocampal formation in schizophrenia, 23:385
- Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis, 22:163
- Neurobiology**
- Evaluation of treatment-resistant schizophrenia, 23:663
- Schizophrenia and nicotine use: Report of a pilot smoking cessation program and review of neurobiological and clinical issues, 23:247
- Neuroimaging. See also specific imaging techniques**
- Neuroimaging and the cognitive neuroscience of schizophrenia, 22:703
- Neuroleptic malignant syndrome**
- Medical complications of new antipsychotic drugs, 22:475
- Neuroleptic intolerance, 23:567
- Neuroleptics. See also Antipsychotic drugs; also specific drugs by name**
- Accelerated osteoporosis in psychiatric patients: Possible pathophysiological processes, 22:447
- Determinants of medication compliance in schizophrenia: Empirical and clinical findings, 23:637
- HIV/AIDS risks as a consequence of schizophrenia, 23:675
- The interface between dopamine neurons and the amygdala: Implications for schizophrenia, 23:471
- Medical comorbidity in schizophrenia, 22:413
- Neuroleptic intolerance, 23:567
- Risperidone: How good is the evidence for efficacy?, 23:155
- Schizophrenia, Alzheimer's disease, and anti-inflammatory agents, 22:1
- Schizophrenia and HIV, 22:465
- Seizures and schizophrenia, 23:611
- Treatment of tardive dyskinesia, 23:583
- Neurologic side effects**
- Neuroleptic intolerance, 23:567
- Neuropathology. See also Neuroanatomy**
- Anatomy of schizophrenia revisited, 23:373
- The basal ganglia and cognitive pattern generators, 23:459
- Cortical development and thalamic pathology in schizophrenia, 23:483
- Functional and anatomical aspects of prefrontal pathology in schizophrenia, 23:437, 517
- Functional brain imaging and the neuropathology of schizophrenia, 23:525
- On localizing schizophrenic neuropathology, 23:537
- The neuroanatomies of schizophrenia, 23:367
- The neuroanatomy of schizophrenia: Editors' introduction, 23:365
- Neuropathology of schizophrenia: Cortex, thalamus, basal ganglia, and neurotransmitter-specific projection systems, 23:403
- Postmortem studies of the hippocampal formation in schizophrenia, 23:385
- Schizophrenia and disordered neural circuitry, 23:529
- Seizures and schizophrenia, 23:611
- Temporolimbic or transcallosal connections: Where is the primary lesion in schizophrenia and what is its nature?, 23:521

The temporolimbic system theory of paranoid schizophrenia, 23:513

The temporolimbic system theory of positive schizophrenic symptoms, 23:423

What an archaeological dig can tell us about macro- and microcircuitry in brains of schizophrenia subjects, 23:503

Neuropsychology

Common sense, insight, and neuropsychological test performance in schizophrenia patients, 22:635

Neurotoxicity

Discussion of Bogerts' temporolimbic system theory of paranoid schizophrenia, 23:533

Nicotine

Medical comorbidity in schizophrenia, 22:413

Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Nicotine dependence

Nicotinic receptor function in schizophrenia, 22:431

Schizophrenia and nicotine use: Report of a pilot smoking cessation program and review of neurobiological and clinical issues, 23:247

Smoking and vulnerability for schizophrenia, 22:405

Nitric oxide

Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis, 22:163

NMDA. *See* N-methyl-D-aspartate

O

Ocular side effects

Neuroleptic intolerance, 23:567

Olfactory hallucinations

Deviant olfactory experiences as indicators of risk for psychosis, 22:371

Scale for rating olfactory hallucinations and other olfactory experiences, 22:381

Onset of psychosis. *See* First-episode psychosis

Opiates

Motivation to quit using substances among individuals with schizophrenia: Implications for a motivation-based treatment model, 23:229

Opioids

Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Osteoporosis

Accelerated osteoporosis in psychiatric patients: Possible pathophysiological processes, 22:447

Outcome. *See* Course and outcome

P

PANSS. *See* Positive and Negative Syndrome Scale

Paranoia

Discussion of Bogerts' temporolimbic system theory of paranoid schizophrenia, 23:533

The temporolimbic system theory of paranoid schizophrenia, 23:513

The temporolimbic system theory of positive schizophrenic symptoms, 23:423

Paranoid schizophrenia

First person account: Paranoid schizophrenia—A sibling's story, 22:557

Parenting issues

Sexuality, reproduction, and family planning in women with schizophrenia, 23:623

Perceptual Aberration Scale

Deviant olfactory experiences as indicators of risk for psychosis, 22:371

Perseveration

Perseveration in schizophrenia, 23:63

PET scans. *See* Positron emission tomography

Pharmacotherapy. *See also specific drugs and classes of drugs by name*

Clinical challenges in the psychopharmacology of schizophrenia: Editors' introduction, 23:563

Determinants of medication compliance in schizophrenia: Empirical and clinical findings, 23:637

The evaluation and treatment of first-episode psychosis, 23:653

Evaluation of treatment-resistant schizophrenia, 23:663

First person account: Meaning of psychoses, 23:541

Foreword, 23:179

HIV/AIDS risks as a consequence of schizophrenia, 23:675

Motivation to quit using substances among individuals with schizophrenia: Implications for a motivation-based treatment model, 23:229

Neuroleptic intolerance, 23:567

Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Seizures and schizophrenia, 23:611

Sexuality, reproduction, and family planning in women with schizophrenia, 23:623

Substance abuse and schizophrenia: Editor's introduction, 23:181

Treatment of tardive dyskinesia, 23:583

Place conditioning

Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats, 23:203

Placebo

Placebo washout in trials of antipsychotic drugs, 22:567

Polydipsia

Medical comorbidity in schizophrenia, 22:413

Problems and progress in the diagnosis and treatment of polydipsia and hyponatremia, 22:455

Polyuria

Problems and progress in the diagnosis and treatment of polydipsia and hyponatremia, 22:455

Positive and Negative Syndrome Scale

First-episode schizophrenia: I. Early course parameters, 22:241

Identifying subtypes of schizophrenia by cluster analyses, 22:545

Positive symptoms

Identifying subtypes of schizophrenia by cluster analyses, 22:545

The neuroanatomies of schizophrenia, 23:367

Positive and negative symptoms: Is their change related?, 22:577

The temporolimbic system theory of positive schizophrenic symptoms, 23:423

Positron emission tomography

Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis, 22:163

Postmortem studies

The neuroanatomy of schizophrenia: Editors' introduction, 23:365

Neuropathology of schizophrenia: Cortex, thalamus, basal ganglia, and neurotransmitter-specific projection systems, 23:403

Postmortem studies of the hippocampal formation in schizophrenia, 23:385

Pregnancy. See Prenatal infections; Reproductive issues; Viral infections

Premorbid Adjustment Scale

First-episode schizophrenia: II. Premorbid patterns by gender, 22:257

Prenatal infections. See also Viral infections

Prenatal exposure to influenza and increased cerebrospinal fluid spaces in schizophrenia, 22:521

Present State Examination

The long-term course of childhood-onset schizophrenia: A 42-year followup, 23:105

Primates

Functional and anatomical aspects of prefrontal pathology in schizophrenia, 23:437, 517

The interface between dopamine neurons and the amygdala: Implications for schizophrenia, 23:471

Process analysis

What do relatives of people with schizophrenia find helpful about family intervention?, 23:341

Prodromal phase

Earlier detection and intervention in schizophrenia: Unsolved questions, 22:347

Early detection and intervention in schizophrenia: Research, 22:327

Monitoring and care of young people at incipient risk of psychosis, 22:283

The prodromal phase of first-episode psychosis: Past and current conceptualizations, 22:353

Psilocybin

A cognitive neuroscience view of schizophrenic thought disorder, 23:29

Psychoeducation

Coping with negative symptoms of schizophrenia: Patient and family perspectives, 23:329

Impact of brief family psychoeducation on self-efficacy, 22:41

Psychopharmacology. See Pharmacotherapy

Psychoses. See also First-episode psychosis

Common sense, insight, and neuropsychological test performance in schizophrenia patients, 22:635

Convulsive therapy in schizophrenia?, 22:27

Deviant olfactory experiences as indicators of risk for psychosis, 22:371

First person account: Meaning of psychoses, 23:541

Psychosis and violence: The case for a content analysis of psychotic experience, 22:91

Risk factors of psychosis: Identifying vulnerable populations premorbidly, 22:223

Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations, 23:147

Substance use disorder and the early course of illness in schizophrenia and affective psychosis, 23:195

Psychosocial functioning

Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia, 23:19

Psychosocial treatment

Determinants of medication compliance in schizophrenia: Empirical and clinical findings, 23:637

Motivation to quit using substances among individuals with schizophrenia: Implications for a motivation-based treatment model, 23:229

Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Psychotherapy

Foreword, 23:179

Substance abuse and schizophrenia: Editors' introduction, 23:181

Psychotic disorders

Course and outcome for schizophrenia versus other psychotic patients: A longitudinal study, 23:287

R

rCBF. See Regional cerebral blood flow

Reaction time

What determines Continuous Performance Task performance?, 22:643

Regional cerebral blood flow

Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis, 22:163

Relapse prediction

Patient attributes and expressed emotion as risk factors for psychotic relapse, 23:119

Relapse prevention

Schizophrenia and nicotine use: Report of a pilot smoking cessation program and review of neurobiological and clinical issues, 23:247

Relational Control Coding System

Communication patterns and expressed emotion in families of persons with mental disorders, 22:671

Relatives. See Families; Siblings

Representations

Functional disorganization of representations in schizophrenia, 22:383

Reproductive issues

Clinical challenges in the psychopharmacology of schizophrenia: Editors' introduction, 23:563
Familial risks and reproductive fitness in schizophrenia, 22:191
HIV/AIDS risks as a consequence of schizophrenia, 23:675
Sexuality, reproduction, and family planning in women with schizophrenia, 23:623

Respiratory side effects

Neuroleptic intolerance, 23:567

Rheumatoid arthritis

Medical comorbidity in schizophrenia, 22:413

Risk factors. See also Vulnerability factors

Deviant olfactory experiences as indicators of risk for psychosis, 22:371

Early detection and intervention with schizophrenia: Rationale, 22:201

Familial risks and reproductive fitness in schizophrenia, 22:191

Genes, experience, and chance in schizophrenia—Positioning for the 21st century, 23:547

Monitoring and care of young people at incipient risk of psychosis, 22:283

Patient attributes and expressed emotion as risk factors for psychotic relapse, 23:119

Seizures and schizophrenia, 23:611

Risperidone

Medical complications of new antipsychotic drugs, 22:475

Risperidone: How good is the evidence for efficacy?, 23:155

S

SAFE. See Social-Adaptive Functioning Evaluation

Scales

Scale for rating olfactory hallucinations and other olfactory experiences, 22:371

Scales for the Assessment of Positive and Negative Symptoms

Positive and negative symptoms: Is their change related?, 22:577

Schedule for the Assessment of Negative Symptoms, 22:139

Schedule for the Assessment of Positive Symptoms, 22:139

Schizoaffective disorder

Clozapine eligibility among State hospital patients, 22:15

Longitudinal courses of thought disorder in schizophrenia and schizoaffective disorder, 23:273

Schizotypal personality disorder

Abnormal orienting in schizotypal personality disorder, 23:75

Childhood behavior precursors of schizotypal personality disorder, 23:93

The factor structure of schizotypal symptoms in a clinical population, 22:501

Familial risks and reproductive fitness in schizophrenia, 22:191

The structure of *DSM-III-R* schizotypal personality disorder diagnosed by direct interviews, 23:83

Schizotypal Personality Questionnaire

Abnormal orienting in schizotypal personality disorder, 23:75

Schizotypy

The factorial structure of schizotypy: Part I. Affinities with syndromes of schizophrenia, 22:611

The factorial structure of schizotypy: Part II. Cognitive asymmetry, arousal, handedness, and sex, 22:621

Occupations, factors, and schizophrenia, 22:11

Self-report measures of schizotypy as indices of familial vulnerability to schizophrenia, 22:511

SCOR

Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia, 23:19

Seizures

Seizures and schizophrenia, 23:611

Self-monitoring

Functional brain imaging and the neuropathology of schizophrenia, 23:437, 517

Self-reports

Self-report measures of schizotypy

as indices of familial vulnerability to schizophrenia, 22:511

Semantic priming

A cognitive neuroscience view of schizophrenic thought disorder, 23:29

Sensory deficits

Medical comorbidity in schizophrenia, 22:413
Nicotinic receptor function in schizophrenia, 22:431

Sentence Span

Frontal/executive impairments in schizophrenia, 22:125

Serotonin

Functional and anatomical aspects of prefrontal pathology in schizophrenia, 23:437, 517
Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Severe mental illness

Illness severity and treatment services for dually diagnosed severely mentally ill outpatients, 23:239

Sexual dysfunction

Neuroleptic intolerance, 23:567
Sexuality, reproduction, and family planning in women with schizophrenia, 23:623

Sexuality issues

Clinical challenges in the psychopharmacology of schizophrenia: Editors' introduction, 23:563
HIV/AIDS risks as a consequence of schizophrenia, 23:675
Physical and sexual assault history in women with serious mental illness: Prevalence, correlates, treatment, and future research directions, 23:685
Sexuality, reproduction, and family planning in women with schizophrenia, 23:623

SFRT-2. *See* Situational Feature Recognition Test, Version 2

Siblings

Anomalous cerebral asymmetry and language processing in schizophrenia, 23:255

Side effects

Medical complications of new antipsychotic drugs, 22:475
Neuroleptic intolerance, 23:567

Signal-to-noise ratio

A cognitive neuroscience view of schizophrenic thought disorder, 23:29

Single photon emission tomography

Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis, 22:163

Situational Feature Recognition Test, Version 2

Situational familiarity and feature recognition in schizophrenia, 22:153

Skin conductance

Abnormal orienting in schizotypal personality disorder, 23:75
Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia, 23:19

Smoking

Medical comorbidity in schizophrenia, 22:413
Nicotinic receptor function in schizophrenia, 22:431
Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215
Schizophrenia and nicotine use: Report of a pilot smoking cessation program and review of neurobiological and clinical issues, 23:247
Smoking and vulnerability for schizophrenia, 22:405

Social-Adaptive Functioning Evaluation

Social-Adaptive Functioning Evaluation (SAFE): A rating scale for geriatric psychiatric patients, 23:131

Social class. *See* Demographic factors

Social functioning.

See also Psychosocial functioning
Are traditional societies schizophrenogenic?, 23:357
Cue availability and affect perception in schizophrenia, 22:535
Early detection and intervention for initial episodes of schizophrenia, 22:271
Occupations, factors, and schizophrenia, 22:11
Situational familiarity and feature recognition in schizophrenia, 22:153
Social-Adaptive Functioning Evaluation (SAFE): A rating scale for geriatric psychiatric patients, 23:131
Time use of unemployed and employed single male schizophrenia subjects, 22:659

Social Knowledge Questionnaire

Common sense, insight, and neuropsychological test performance in schizophrenia patients, 22:635

Sociocentric indicators

Cross-ethnic symptom differences in schizophrenia: The influence of culture and minority status, 23:305

Socioeconomic factors

Clinical benefits of paid work activity in schizophrenia, 22:51
First person account: Social, economic, and medical effects of schizophrenia, 22:183
Occupations, factors, and schizophrenia, 22:11

Speciation

Temporolimbic or transcallosal connections: Where is the primary

lesion in schizophrenia and what is its nature?, 23:521

Speech generation

Speech fluency and schizophrenic negative signs, 23:171

Stereotypy

The basal ganglia and cognitive pattern generators, 23:459

Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats, 23:203

Stimulants

Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Striatum. See Neuroanatomy; Neuropathology

Stroop test

Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia, 23:19

Structured Interview for DSM-III-R Personality Disorders

The structure of DSM-III-R schizotypal personality disorder diagnosed by direct interviews, 23:83

Subjective experiences

First person account: A voice from another closet, 22:399

First person account: How I cope, 23:697

First person account: Living with mental illness, 23:349

First person account: Meaning of psychoses, 23:541

First person account: Paranoid schizophrenia—A sibling's story, 22:557

First person account: Schizophrenia, 22:727

First person account: Social, economic, and medical effects of schizophrenia, 22:183

First person account: The end of two roads, 23:163

Substance abuse

Determinants of medication compliance in schizophrenia: Empirical and clinical findings, 23:637

Differential diagnosis of substance-induced psychosis and schizophrenia in patients with substance use disorder, 23:187

Foreword, 23:179

HIV/AIDS risks as a consequence of schizophrenia, 23:675

Illness severity and treatment services for dually diagnosed severely mentally ill outpatients, 23:239

Medical comorbidity in schizophrenia, 22:413

Motivation to quit using substances among individuals with schizophrenia: Implications for a motivation-based treatment model, 23:229

Patient attributes and expressed emotion as risk factors for psychotic relapse, 23:119

Pharmacotherapy of schizophrenia patients with comorbid substance abuse, 23:215

Substance abuse and schizophrenia: Editors' introduction, 23:181

Substance use disorder and the early course of illness in schizophrenia and affective psychosis, 23:195

Substantia nigra. See Neuroanatomy

Subtypes of schizophrenia

Cognitive inhibition and schizophrenic symptom subgroups, 22:139

Identifying subtypes of schizophrenia by cluster analyses, 22:545

Supersensitivity

Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats, 23:203

Suppressive agents

Treatment of tardive dyskinesia, 23:583

Symptoms. See also Positive symptoms;

Negative symptoms; *specific symptoms*

Cross-ethnic symptom differences in schizophrenia: The influence of culture and minority status, 23:305

Physical and sexual assault history in women with serious mental illness: Prevalence, correlates, treatment, and future research directions, 23:685

T

Tardive dyskinesia

Medical complications of new antipsychotic drugs, 22:475

Treatment of tardive dyskinesia, 23:583

Teacher ratings

Childhood behavior precursors of schizotypal personality disorder, 23:93

Risk factors of psychosis: Identifying vulnerable populations premorbidly, 22:223

Thalamus. See Neuroanatomy; Neuropathology

Therapeutic impacts

What do relatives of people with schizophrenia find helpful about family intervention?, 23:341

Therapy. See Pharmacotherapy

Thought disorder

A cognitive neuroscience view of schizophrenic thought disorder, 23:29

Longitudinal courses of thought disorder in schizophrenia and schizoaffective disorder, 23:273

Perseveration in schizophrenia, 23:63

Treatment. See also Pharmacotherapy; *specific treatment by name*

Clozapine eligibility among State hospital patients, 22:15

The evaluation and treatment of first-episode psychosis, 23:653

First person account: Meaning of psychoses, 23:541

Illness severity and treatment services for dually diagnosed severely mentally ill outpatients, 23:239

Physical and sexual assault history in women with serious mental illness: Prevalence, correlates, treatment, and future research directions, 23:685

Treatment of tardive dyskinesia, 23:583

Treatment compliance

Determinants of medication compliance in schizophrenia: Empirical and clinical findings, 23:637

Illness severity and treatment services for dually diagnosed severely mentally ill outpatients, 23:239

Neuroleptic intolerance, 23:567

Treatment complications

Medical complications of new antipsychotic drugs, 22:475

Treatment delay

EPPIC: An evolving system of early detection and optimal management, 22:305

Treatment-resistant patients

Clinical challenges in the psychopharmacology of schizophrenia: Editors' introduction, 23:563

Clozapine eligibility among State hospital patients, 22:15

Convulsive therapy in schizophrenia?, 22:27

Evaluation of treatment-resistant schizophrenia, 23:663

U

Urinary problems

Neuroleptic intolerance, 23:567

V

Ventral tegmental area. *See* Neuroanatomy

Violence

Evaluation of treatment-resistant schizophrenia, 23:663

Physical and sexual assault history in women with serious mental illness: Prevalence, correlates, treatment, and future research directions, 23:685

Psychosis and violence: The case for a content analysis of psychotic experience, 22:91

Viral infections. *See also* Prenatal infections

Prenatal exposure to influenza and increased cerebrospinal fluid spaces in schizophrenia, 22:521

Voice acoustics

Speech fluency and schizophrenic negative signs, 23:171

Vulnerability factors. *See also* Risk factors

Risk factors of psychosis: Identifying vulnerable populations premorbidly, 22:223

Self-report measures of schizotypy as indices of familial vulnerability to schizophrenia, 22:511

Smoking and vulnerability for schizophrenia, 22:405

W

Wechsler Adult Intelligence Scale—Revised

Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia, 23:19

Weight gain

Medical complications of new antipsychotic drugs, 22:475

Withdrawal effects

Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal, 22:591

Medication-free intervals and schizophrenia research: Editors' introduction, 23:1

Research in schizophrenia and the discontinuation of antipsychotic medications, 23:3

The risk of medication-free research, 23:11

Words Span Forward

Frontal/executive impairments in schizophrenia, 22:125

Work. *See* Employment

Working memory

Functional and anatomical aspects of prefrontal pathology in schizophrenia, 23:437